Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors

作者
Robert M. Sharkey,Allyson J. Ocean,Alexander Starodub,Aditya Bardia,Michael J. Guarino,Wells A. Messersmith,Jordan D. Berlin,Vincent J. Picozzi,Rebecca Moroose,William A. Wegener,Pius P. Maliakal,Serengulam V. Govindan,David M. Goldenberg
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:77 (13_Supplement): 3734-3734 被引量:4
标识
DOI:10.1158/1538-7445.am2017-3734
摘要

Abstract BACKGROUND: Sacituzumab govitecan (IMMU-132), an ADC targeting Trop-2, an antigen present in many solid tumors, uses SN-38, a topoisomerase I inhibitor that has nanomolar potency derived from irinotecan (IRI), and a pH sensitive linker that releases SN-38 gradually (in vitro, 50% released per 1 day in serum). Clinical studies in patients (pts) with diverse solid tumors have shown manageable toxicity (dose-limiting neutropenia, diarrhea but lower incidence than IRI) and encouraging efficacy. METHODS: Conjugate and IgG were monitored in pts given 8 (N = 24) or 10 mg/kg (N = 29) by ELISA. SN-38 and glucuronidated SN-38 (SN-38G) were measured by reversed-phase HPLC. SN-38 and SN-38G levels are expressed as the amount of drug dissociated from the conjugate (i.e., Free SN-38) and the amount bound to the IgG (Total SN-38). UGT1A1 status was determined in baseline blood sample from 146 pts. RESULTS: IMMU-132 cleared with a half-life of 11.7-18.9 h, depending on the assay, while the IgG half-life was 4-5 days, which agrees with in vitro drug-release data. Levels of Free SN-38 at 30 min or 1 d after injection were <2% and ~ 5% of Total SN-38, respectively, indicating most SN-38 in serum is bound to the conjugate. Free SN-38 clears with a half-life of ~20 h, which is consistent with SN-38 clearance in IRI therapy. No correlation was found between Free SN-38 in serum at 30 min and the incidence of severe neutropenia. Total and Free levels of SN-38G were similar, supporting in vitro results indicating that SN-38 is not glucuronidated while bound to the IgG. Free SN-38G levels were lower than Free SN-38 (SN-38G/SN-38 AUC ratio = 0.52), explaining the lower incidence of severe diarrhea. PK parameters for 8 and 10 mg/kg group were similar; no major differences in toxicity. UGT1A1 status showed 43% and 44% with *1*1 and *1*28 haplotype, respectively, and 13% with *28*28 haplotype, which is associated with higher risk of severe neutropenia and diarrhea for IRI therapy. With IMMU-132, 58% of the *28*28 pts had severe neutropenia compared to ~40% of the *1*1 and *1*28 pts, and 16% of the *28*28 pts had grade 3 diarrhea compared to 5-8% of the *1*1 and *1*28. In 3 of 4 cancer indications, objective response rate and clinical benefit ratio favored the 10 mg/kg group. CONCLUSION: IMMU-132 cleared as predicted from in vitro serum stability data, with no difference between the 8 and 10 mg/kg groups. Current data show neutropenia did not correlate with Free SN-38 levels in serum at 30 min, and low SN-38G levels support the lower incidence of severe diarrhea. While pts with the *28*28 haplotype had a somewhat higher incidence of severe neutropenia or diarrhea than *1*1 and *1*28 pts, the overall incidence of each is small, suggesting toxicity management rather than screening is appropriate. With no major difference in safety and PK, but improved responses with 10 mg/kg, 10 mg/kg is selected for future clinical studies. Citation Format: Robert M. Sharkey, Allyson J. Ocean, Alexander N. Starodub, Aditya Bardia, Michael Guarino, Wells A. Messersmith, Jordan D. Berlin, Vincent J. Picozzi, Rebecca Moroose, William A. Wegener, Pius Maliakal, Serengulam V. Govindan, David M. Goldenberg. Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3734. doi:10.1158/1538-7445.AM2017-3734

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sufu_jony的应助被聪明威采纳,获得10
刚刚
TT完成签到 ,获得积分10
刚刚
orixero的应助被Maestro_S采纳,获得10
1秒前
邓统浩发布了新的文献求助10
1秒前
斯文败类的应助被zaq66996采纳,获得10
1秒前
曾经乌完成签到,获得积分10
2秒前
kk完成签到,获得积分10
2秒前
欢呼亦竹完成签到 ,获得积分10
2秒前
无极微光的应助被惊蛰海采纳,获得20
2秒前
why完成签到,获得积分10
2秒前
大胆的灵雁完成签到,获得积分10
3秒前
3秒前
HHHH完成签到,获得积分10
3秒前
蛀虫完成签到 ,获得积分10
4秒前
4秒前
迅速金毛完成签到,获得积分10
4秒前
图书馆完成签到,获得积分10
4秒前
5秒前
Ttttt发布了新的文献求助10
5秒前
邓统浩完成签到,获得积分10
5秒前
吃饭饭发布了新的文献求助10
5秒前
爱唱狐狸的番茄小子完成签到,获得积分10
5秒前
6秒前
zz321完成签到,获得积分0
6秒前
洁净如音完成签到,获得积分10
6秒前
MMQ完成签到,获得积分10
6秒前
111发布了新的文献求助10
6秒前
小张在进步完成签到,获得积分10
6秒前
6秒前
6秒前
尊敬的寄松的应助被Samuel采纳,获得30
6秒前
7秒前
规格严格功夫到家完成签到,获得积分10
7秒前
威武的友琴完成签到,获得积分10
7秒前
Hello的应助被吃完睡h采纳,获得10
7秒前
7秒前
lemon完成签到,获得积分10
7秒前
所所的应助被北岭梅花香到骨采纳,获得10
7秒前
跳跃小笼包完成签到,获得积分10
8秒前
隐形曼青的应助被hbutsj采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159790
求助须知:如何正确求助?哪些是违规求助? 9555224
关于积分的说明 21726021
捐赠科研通 7749765
什么是DOI,文献DOI怎么找? 3427296
关于科研通互助平台的介绍 2552375
邀请新用户注册赠送积分活动 2471654